JP2016502517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502517A5 JP2016502517A5 JP2015540800A JP2015540800A JP2016502517A5 JP 2016502517 A5 JP2016502517 A5 JP 2016502517A5 JP 2015540800 A JP2015540800 A JP 2015540800A JP 2015540800 A JP2015540800 A JP 2015540800A JP 2016502517 A5 JP2016502517 A5 JP 2016502517A5
- Authority
- JP
- Japan
- Prior art keywords
- sortilin
- use according
- control
- compound
- calcification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721727P | 2012-11-02 | 2012-11-02 | |
| US61/721,727 | 2012-11-02 | ||
| PCT/US2013/067969 WO2014071131A1 (en) | 2012-11-02 | 2013-11-01 | Sortilin 1 is a novel inducer of vascular calcification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502517A JP2016502517A (ja) | 2016-01-28 |
| JP2016502517A5 true JP2016502517A5 (https=) | 2016-08-25 |
| JP6239635B2 JP6239635B2 (ja) | 2017-11-29 |
Family
ID=50628077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540800A Active JP6239635B2 (ja) | 2012-11-02 | 2013-11-01 | 血管石灰化の誘導因子であるソルチリン１ |
Country Status (3)
| Country | Link |
|---|---|
| US (3) | US9822366B2 (https=) |
| JP (1) | JP6239635B2 (https=) |
| WO (1) | WO2014071131A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| CN106538029B (zh) | 2014-06-27 | 2020-10-16 | 泰科弗勒克斯公司 | 用于发送数据单元的方法和装置 |
| WO2016164608A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Methods of screening for sortilin binding antagonists |
| SI3280441T1 (sl) | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| JP6632116B2 (ja) * | 2015-08-20 | 2020-01-15 | 国立大学法人広島大学 | 破骨細胞形成および／または機能抑制剤、破骨細胞形成および／または機能促進剤並びに破骨細胞形成および／または機能を抑制または促進する薬剤のスクリーニング法 |
| US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| LT3618928T (lt) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilino antikūnai ir jų panaudojimo būdai |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551990B2 (en) | 1998-12-07 | 2003-04-22 | University Of Washington | Methods of inhibiting ectopic calcification |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| JP2007530029A (ja) | 2004-03-26 | 2007-11-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | アネキシンｉｉ及びその使用 |
| WO2006047820A1 (en) | 2004-11-01 | 2006-05-11 | Newsouth Innovations Pty Limited | Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation |
| JP2008239488A (ja) | 2005-07-07 | 2008-10-09 | Saitama Medical Univ | 動脈硬化の治療剤 |
| DK2851084T3 (en) * | 2008-05-22 | 2018-07-30 | H Lundbeck As | Modulation of Vps10p domain receptors for the treatment of cardiovascular disease |
| WO2009143519A2 (en) * | 2008-05-23 | 2009-11-26 | The Johns Hopkins University | Biomarkers for myocardial ischemia |
| US8168390B2 (en) * | 2009-05-27 | 2012-05-01 | University Of Regensburg | Method and apparatus for diagnosing age-related macular degeneration |
| US20130115222A1 (en) * | 2010-06-15 | 2013-05-09 | Cornell University | Methods of limiting microvascular damage following acute myocardial ischemia |
| JP5852433B2 (ja) * | 2010-12-20 | 2016-02-03 | 株式会社ビー・エム・エル | ソルチリンによる動脈硬化の判定方法 |
-
2013
- 2013-11-01 JP JP2015540800A patent/JP6239635B2/ja active Active
- 2013-11-01 US US14/439,951 patent/US9822366B2/en active Active
- 2013-11-01 WO PCT/US2013/067969 patent/WO2014071131A1/en not_active Ceased
-
2017
- 2017-10-13 US US15/783,947 patent/US10508278B2/en active Active
-
2019
- 2019-10-24 US US16/662,776 patent/US11274306B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502517A5 (https=) | ||
| Pronin et al. | Ectopically expressed olfactory receptors OR51E1 and OR51E2 suppress proliferation and promote cell death in a prostate cancer cell line | |
| Mencke et al. | Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue | |
| Uyama et al. | Hepatic stellate cells express synemin, a protein bridging intermediate filaments to focal adhesions | |
| EP3740246B9 (en) | Disrupting the linc complex for treating laminopathy | |
| HUE030738T2 (en) | Screening for anti-cancer compounds using netrin-1 activity | |
| US20130195863A1 (en) | Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases | |
| Nozawa et al. | Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass | |
| Simes et al. | Purification of matrix Gla protein from a marine teleost fish, Argyrosomus regius: calcified cartilage and not bone as the primary site of MGP accumulation in fish | |
| US20170114329A1 (en) | Scalable organotypic models of tumor dormancy | |
| US20070293579A1 (en) | Use of carp inhibitors for the treatment of heart diseases | |
| Hadjiargyrou et al. | The E11 osteoblastic lineage marker is differentially expressed during fracture healing | |
| Velasco-Velázquez et al. | Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells | |
| AU2001295457A1 (en) | Use of CARP inhibitors for the treatment of heart diseases | |
| Jasnic-Savovic et al. | Differential expression and localization of Ankrd2 isoforms in human skeletal and cardiac muscles | |
| CN117802046A (zh) | 一种永生化细胞系及其构建方法和应用 | |
| Mannikarottu et al. | Altered expression of thin filament‐associated proteins in hypertrophied urinary bladder smooth muscle | |
| US20040105860A1 (en) | Cell modulation using a cytoskeletal protein | |
| Wookey et al. | The elevated expression of calcitonin receptor by cells recruited into the endothelial layer and neo-intima of atherosclerotic plaque | |
| US20250345404A1 (en) | Compositions and methods for treating heart failure | |
| EP4454663A1 (en) | Therapeutic or prophylactic agent for heart attack, heart fibrosis, or heart failure, where htra3 is therapeutic target | |
| CN102166346A (zh) | Lrrc10小分子及其在制备治疗心肌肥厚药物中的应用 | |
| Senatus | Receptor for Advanced Glycation End Products (Ager) and Diaphanous-1 (Drf1) Suppress Regression of Diabetic Atherosclerosis | |
| US20050250717A1 (en) | Chromatin remodeling protein as a marker expressed by stromal progenitor cells | |
| JP5307555B2 (ja) | カルシニューリン抑制のペプチド |